BRIEF published on 02/16/2026 at 07:35, 8 months 12 days ago Nicox Receives Positive Feedback from FDA for NCX 470 NDA FDA Nicox Glaucoma Treatment NCX 470 NDA Submission
PRESS RELEASE published on 02/16/2026 at 07:30, 8 months 12 days ago Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 Nicox receives positive feedback from pre-NDA meeting with U.S. FDA for NCX 470, on track for NDA submission in summer 2026. NCX 470 lowers intraocular pressure in glaucoma patients FDA Nicox NCX 470 Intraocular Pressure Pre-NDA
BRIEF published on 02/12/2026 at 07:35, 8 months 16 days ago Nicox maintains its PEA-PME status for 2026 PEA-PME Euronext Growth Paris Investment Ophthalmology Nicox
BRIEF published on 02/10/2026 at 07:35, 8 months 18 days ago Nicox to Present Key Data at AGS Annual Meeting 2026 Clinical Trials Glaucoma Nicox NCX 470 AGS 2026
PRESS RELEASE published on 02/10/2026 at 07:30, 8 months 18 days ago Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Nicox to present NCX 470 Phase 3 data at AGS Annual Meeting 2026 with podium presentations showcasing clinical study results and efficacy of the ophthalmic solution Clinical Study Ophthalmology Nicox NCX 470 AGS Annual Meeting 2026
BRIEF published on 01/20/2026 at 07:35, 9 months 11 days ago Nicox announces its participation in several congresses in 2026 Glaucoma Ophthalmology Nicox NCX 470 Congress 2026
BRIEF published on 01/20/2026 at 07:35, 9 months 11 days ago Nicox Announces 2026 Conference Participation and Data Presentations Scientific Data Ophthalmology NCX 470 Conference Participation 2026 Events
PRESS RELEASE published on 01/20/2026 at 07:30, 9 months 11 days ago Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations Nicox to attend key ophthalmology conferences and present scientific data at AGS 2026 Annual Meeting. Management team available for meetings. Developing innovative eye health solutions Conference Scientific Data Ophthalmology Nicox Eye Health
BRIEF published on 12/16/2025 at 07:35, 10 months 15 days ago Nicox Finalizes Key Data for NCX 470 NDA Submission by H1 2026 Clinical Trials Ophthalmology Nicox NCX 470 NDA Submission
PRESS RELEASE published on 12/16/2025 at 07:30, 10 months 15 days ago Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 Nicox completes key data generation for NCX 470 new drug application submission in H1 2026, including clinical trial and stability data. U.S. and China submissions on track FDA Clinical Trials Nicox NCX 470 New Drug Application
Published on 10/30/2026 at 23:35, 1 day ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 5 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 8 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 7 hours 38 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 1 hour ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 5 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 day 1 hour ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 12 hours ago Capital increase through exercise of subscription rights
